Prelude Therapeutics Inc. is a pharmaceutical company in the United States specializing in precision oncology. With an ESG risk rating score of 28.2, the company is classified as medium risk. Prelude Therapeutics Inc. is dedicated to developing small molecule therapies that target key driver mechanisms in cancers with high unmet needs. Their pipeline includes promising candidates like PRT1419, PRT2527, PRT3645, and PRT3789.